Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
691 stopped studies mapped to Malignant Head and Neck Neoplasm and descendants · 92% state a reason
Over the 691 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05073172 | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or… | N/A | withdrawn | Oct 11, 2021 | OHSU Knight Cancer Institute | study staff transition | Other (stated, no rule matched) |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA… | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Novartis has chosen to withdraw support for this trial | Other (stated, no rule matched) |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | N/A | withdrawn | Jun 9, 2022 | Ohio State University Comprehensive Cancer Center | Funding lapse | Funding |
| NCT04659369 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in… | Phase 1 | terminated | Dec 9, 2020 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Difficult to recruit subjects | Enrollment / accrual |
| NCT04936841 | Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck… | Phase 2 | terminated | Jun 23, 2021 | University of Wisconsin, Madison | study closed by the sponsor | Other (stated, no rule matched) |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid… | Phase 2 | withdrawn | Feb 1, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive…(ANAPLAST-NEO) | Phase 2 | withdrawn | Feb 4, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT03345732 | Intraoperative Evaluation Using ICG and SPY Fluorescence to Prevent Wound Complications… | — | withdrawn | Nov 17, 2017 | University Health Network, Toronto | PI has been having difficulties obtaining ICG for this project. | Other (stated, no rule matched) |
| NCT03602066 | Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head/Neck Radiotherapy | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Study terminated by pharmaceutical company | Sponsor / business decision |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant… | Phase 1 | withdrawn | Jul 25, 2022 | Ikena Oncology | Sponsor Decision | Sponsor / business decision |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for…(NPC) | N/A | terminated | Jan 3, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced… | N/A | withdrawn | Oct 28, 2019 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for… | N/A | terminated | Feb 8, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of… | N/A | terminated | Jan 18, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in… | Phase 1 / Phase 2 | terminated | Oct 29, 2021 | NKGen Biotech, Inc. | Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best… | Other (stated, no rule matched) |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant,… | Phase 1 | terminated | Nov 10, 2020 | Washington University School of Medicine | Ipsen bought out Epizyme | Other (stated, no rule matched) |
| NCT05263648 | Virtual Reality Software to Reduce Stress in Cancer Patients(OU-SCC VR) | N/A | withdrawn | Mar 2, 2022 | University of Oklahoma | due to an issue with the software developer that cannot be resolved. | Other (stated, no rule matched) |
| NCT05331131 | Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity… | Phase 2 | withdrawn | Apr 15, 2022 | Northwell Health | Study team not moving forward with protocol | Other (stated, no rule matched) |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | Phase 2 | terminated | Mar 31, 2020 | Vanderbilt-Ingram Cancer Center | Funding ended | Funding |
| NCT05724849 | Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer | Phase 2 | withdrawn | Feb 13, 2023 | Vanderbilt University Medical Center | Issues with funding | Funding |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug… | Phase 1 / Phase 2 | terminated | May 11, 2017 | CytomX Therapeutics | Covid Pandemic; Business Decision to separate Phase 2 to new study | COVID-19 / pandemic |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated…(AcceleRET-MTC) | Phase 3 | withdrawn | Feb 18, 2021 | Hoffmann-La Roche | Due to several logistical challenges during start-up which could not be overcome study was… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | Phase 2 | terminated | Nov 18, 2020 | MacroGenics | Based on internal review of safety data | Safety / toxicity |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122…(PANTHEoN) | Phase 1 | withdrawn | May 19, 2021 | Jennifer Choe | Funding | Funding |
| NCT02892487 | Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated…(RORC) | N/A | terminated | Sep 8, 2016 | Rennes University Hospital | For financial reasons and speed of recruitment was much slower than expected, inclusions weren't… | COVID-19 / pandemic |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before… | Phase 1 / Phase 2 | terminated | Aug 7, 2018 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT05073809 | Photoacoustic Imaging of Head and Neck Tumours | — | withdrawn | Oct 12, 2021 | University College, London | Research Fellow left Trust. | Other (stated, no rule matched) |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03875053 | Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage… | N/A | withdrawn | Mar 14, 2019 | Barbara Ann Karmanos Cancer Institute | No accrual | Enrollment / accrual |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Phase 1 / Phase 2 | terminated | Dec 10, 2019 | SecuraBio | The study was terminated due to low enrollment. | Enrollment / accrual |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | terminated | May 27, 2022 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05359692 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or… | Phase 2 | withdrawn | May 4, 2022 | Incyte Biosciences International Sàrl | Business decision; no safety concerns | Safety / toxicity |
| NCT04834349 | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of… | Phase 2 | withdrawn | Apr 8, 2021 | M.D. Anderson Cancer Center | No participants were enrolled | Enrollment / accrual |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous… | Phase 2 | withdrawn | Sep 10, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02524275 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the… | Phase 2 | terminated | Aug 14, 2015 | University of Nebraska | low enrollment | Enrollment / accrual |
| NCT03714906 | Stellate Ganglion Block in Head and Neck Cancer Surgery | N/A | terminated | Oct 22, 2018 | Augusta University | Slow accrual, lack of benefit between intervention and control arms on interim analysis | Efficacy / futility |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive… | Phase 1 / Phase 2 | terminated | Sep 24, 2018 | Cullinan Therapeutics Inc. | Lack of efficacy | Efficacy / futility |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible… | Phase 1 / Phase 2 | terminated | Jul 1, 2008 | Genmab | The decision is based on company re-evaluation of indications to be pursued within SCCHN | Sponsor / business decision |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Phase 2 | terminated | Apr 22, 2016 | Rutgers, The State University of New Jersey | Study Complete | Other (stated, no rule matched) |
| NCT04922112 | Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado(OSA-HN) | N/A | withdrawn | Jun 10, 2021 | University of Colorado, Denver | Unable to find participants, no enrollment | Enrollment / accrual |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 6, 2024source: clinicaltrials